Literature DB >> 167658

Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin polymyxin B, and carbenicillin.

R F D'amato, C Thornsberry, C N Baker, L A Kirven.   

Abstract

The effect of calcium and magnesium on the susceptibility of 13 species of Pseudomonas to tetracycline, gentamicin, polymyxin B, and carbenicillin was measured. The majority of the minimum inhibitory concentrations (MICs) of these antibiotics was increased if these cations were added to the test media. The increases in MICs caused by calcium or magnesium were similar, but the combination of both ions generally caused a greater change than either alone. Although the MIC of polymyxin B was most affected by calcium and magnesium, its interpretive susceptibilities (i.e., whether susceptible or resistant) were least changed. Susceptibility tests on Pseudomonas species probably should be done with Muller-Hinton broth supplemented with physiological concentrations of calcium and magnesium to better approximate the in vivo activity of these antibiotics. When the susceptibility tests were performed with Mueller-Hinton agar, the MICs were slightly less than those obtained with Mueller-Hinton broth supplemented with both cations but greater than those obtained with Mueller-Hinton broth supplemented with individual cations.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 167658      PMCID: PMC429188          DOI: 10.1128/AAC.7.5.596

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Site of action of polymyxin on Pseudomonas aeruginosa: antagonism by cations.

Authors:  B A NEWTON
Journal:  J Gen Microbiol       Date:  1954-06

2.  Reversal of the antibacterial activity of polymyxin by divalent cations.

Authors:  B A NEWTON
Journal:  Nature       Date:  1953-07-25       Impact factor: 49.962

3.  Locus of divalent cation inhibition of the bactericidal action of polymyxin B.

Authors:  C C Chen; D S Feingold
Journal:  Antimicrob Agents Chemother       Date:  1972-11       Impact factor: 5.191

4.  Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium.

Authors:  S D Davis; A Iannetta; R J Wedgwood
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

5.  Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media.

Authors:  L B Reller; F D Schoenknecht; M A Kenny; J C Sherris
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

6.  Activity of aminoglycoside antibiotics aganst Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism.

Authors:  V M Zimelis; G G Jackson
Journal:  J Infect Dis       Date:  1973-06       Impact factor: 5.226

7.  In vitro studies of tobramycin, an aminoglycoside antibiotic.

Authors:  J Dienstag; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1972-01       Impact factor: 5.191

8.  Influence of serum and calcium on the bactericidal activity of gentamicin and carbenicillin on Pseudomonas aeruginosa.

Authors:  S D Davis; A Iannetta
Journal:  Appl Microbiol       Date:  1972-04

9.  Effect of medium composition on the apparent sensitivity of Pseudomonas aeruginosa to gentamicin.

Authors:  L P Garrod; P M Waterworth
Journal:  J Clin Pathol       Date:  1969-09       Impact factor: 3.411

10.  Antagonistic effect of calcium in serum on the activity of tobramycin against Pseudomonas.

Authors:  S D Davis; A Iannetta
Journal:  Antimicrob Agents Chemother       Date:  1972-06       Impact factor: 5.191

  10 in total
  37 in total

1.  Minimal inhibitory concentrations of 34 antimicrobial agents for control strains Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853.

Authors:  R J Fass; J Barnishan
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

2.  Quality control performance in a provincial veterinary diagnostic microbiology laboratory system.

Authors:  J A Lynch; M E Kierstead
Journal:  Can Vet J       Date:  1986-03       Impact factor: 1.008

3.  High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest.

Authors:  Carlos Fernández-Mazarrasa; Olav Mazarrasa; Jorge Calvo; Asunción del Arco; Luis Martínez-Martínez
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

4.  Antibiotic susceptibility of clinical isolates of Listeria monocytogenes.

Authors:  G L Wiggins; W L Albritton; J C Feeley
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

5.  Selection of a reference lot of Mueller-Hinton agar.

Authors:  H M Pollock; A L Barry; T L Gavan; P C Fuchs; S Hansen; C L Thornsberry; H Frankel; S B Forsythe
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

6.  Susceptibility of dysgonic fermenter 2 to antimicrobial agents in vitro.

Authors:  A Verghese; F Hamati; S Berk; B Franzus; S Berk; J K Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

7.  Wide variability in Pseudomonas aeruginosa aminoglycoside results among seven susceptibility testing procedures.

Authors:  J L Staneck; S Glenn; J R DiPersio; P A Leist
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination.

Authors:  T P Felegie; V L Yu; L W Rumans; R B Yee
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

10.  Synergistic effects of miconazole and polymyxin B on microbial pathogens.

Authors:  Silvia Pietschmann; Katrin Hoffmann; Michael Voget; Ulrich Pison
Journal:  Vet Res Commun       Date:  2008-12-16       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.